8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):    July 7, 2009

Medizone International, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State of Other Jurisdiction of Incorporation)

002-93277-D

 87-0412648

(Commission File Number)

(IRS Employer Identification No.)

144 Buena Vista, P.O. Box 742, Stinson Beach, California

    94970

(Address of Principal Executive Offices)

(Zip Code)

(415) 868-0300

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Item 7.01

Regulation FD Disclosure.

On July 7, 2009, Medizone International, Inc. (“the Company”) issued a press release announcing that it has established its own BSL2A certified laboratory located in Innovation Park, Queen’s University at Kingston, Ontario, Canada.

A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.  The Company will also post this document on its corporate website, www.medizoneint.com, under the "Press Releases" link.

In accordance with General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing.

Item 9.01.  Financial Statements and Exhibits.

(d)

Exhibits.  

99

Press Release dated July 7, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.

Date: July 7, 2009

By:  /s/ Edwin G. Marshall

     -----------------------------------------------

Edwin G. Marshall

Chief Executive Officer

2

EX-99

EXHIBIT 99 to Form 8-K dated 7-7-09

MEDIZONE INTERNATIONAL, INC.

San Francisco, California July 7, 2009, Medizone International, Inc. (MZEI.PK) announces it has established its own BSL2A certified laboratory located in Innovation Park, Queen’s University at Kingston, Ontario, Canada.  "This is a fully equipped bio-safety level 2 laboratory dedicated exclusively to Medizone research", stated Dr. Michael Shannon Director of Medical Affairs for Medizone.  "This new laboratory is located in the heart of one of the finest bio-medical communities in the country and will provide a primary research and development platform for the Corporation as it proceeds down what is now a clear path to commercialization with its lead product, AsepticSure™.   Given the outstanding range of bactericidal kill rates we have achieved to date (4.4 log /99.994% to 5 log /99.999%) with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand our scien tific horizons through collaborative arrangements in many diverse and exciting new applications.  The current pandemic of H1 N1 influenza occurring world-wide reminds us how vulnerable we are to new infectious diseases and why new advanced and innovative technologies that combat such infectious agents are seriously needed. The Medizone AsepticSure™ system is just such an innovation in the battle against infections which claim countless lives every day world-wide.  The Company now has a platform to continue an expanded laboratory research program even as it prepares for the commencement of hospital beta testing of its hospital sterilization system later this summer."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4 quarter of this year.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The company disclaims any obligation or intention to update any forward-looking statement.

Investor Relations: 800-953-3350 / web site: www.medizoneint.com

E-mail: operations @ medizoneint.com